Memorial Cancer Institute

Memorial Hospital West

Pembroke Pines, FL

Sorting 2 by

Accepting patients

TRIDENT-1

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

VMD-928

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2